Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancer

Karyopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint.

The failure represents the company's second unsuccessful attempt to expand the blood‑cancer drug into a solid‑tumor indication, and the news sent the shares sharply lower.

Investors reacted negatively, with the stock price plunging after the announcement, underscoring the challenges of repurposing Xpovio for new cancer types.